Breast cancer:: from estrogen to androgen receptor

被引:120
|
作者
Andò, S
De Amicis, F
Rago, V
Carpino, A
Maggiolini, M
Panno, ML
Lanzino, M
机构
[1] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy
[2] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, CS, Italy
关键词
breast cancer; estrogen; androgen;
D O I
10.1016/S0303-7207(02)00105-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and postmenopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E-2. DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E-2 (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E-2 presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E-2 proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E-2 action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574 --> Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E-2 signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E-2. This seems to be related to the inhibitory effects of the over-expressed AR on E-2 genomic action. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [31] Androgen Receptor in Breast Cancer: From Bench to Bedside
    Chen, Mengyao
    Yang, Yunben
    Xu, Kai
    Li, Lili
    Huang, Jian
    Qiu, Fuming
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [32] The androgen receptor in breast cancer: learning from the past
    Michaela J. Higgins
    Antonio C. Wolff
    Breast Cancer Research and Treatment, 2010, 124 : 619 - 621
  • [33] The androgen receptor in breast cancer: learning from the past
    Higgins, Michaela J.
    Wolff, Antonio C.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) : 619 - 621
  • [34] Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
    Niemeier, Leo A.
    Dabbs, David J.
    Beriwal, Sushil
    Striebel, Joan M.
    Bhargava, Rohit
    MODERN PATHOLOGY, 2010, 23 (02) : 205 - 212
  • [35] Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer
    Ximena García
    Andrés Elía
    Lucrecia Galizzi
    María May
    Eunice Spengler
    Paula Martínez Vázquez
    Javier Burruchaga
    Hugo Gass
    Claudia Lanari
    Caroline A. Lamb
    Breast Cancer Research and Treatment, 2020, 180 : 257 - 263
  • [36] Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer
    Garcia, Ximena
    Elia, Andres
    Galizzi, Lucrecia
    May, Maria
    Spengler, Eunice
    Martinez Vazquez, Paula
    Burruchaga, Javier
    Gass, Hugo
    Lanari, Claudia
    Lamb, Caroline A.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (01) : 257 - 263
  • [37] IMMUNOCYTOCHEMICAL ANALYSIS OF ANDROGEN RECEPTOR IN BREAST-CANCER AND CORRELATION WITH ESTROGEN AND PROGESTERONE RECEPTORS
    SCHULZ, TJ
    MOYNES, R
    WILLIS, J
    ABRAHAMSSON, PA
    LIAO, S
    DISANTAGNESE, PA
    LABORATORY INVESTIGATION, 1993, 68 (01) : A19 - A19
  • [38] Estrogen receptor β and breast cancer
    Balfe, PJ
    McCann, AH
    Welch, HM
    Kerin, MJ
    EJSO, 2004, 30 (10): : 1043 - 1050
  • [39] Estrogen receptor and breast cancer
    Sommer, S
    Fuqua, SAW
    SEMINARS IN CANCER BIOLOGY, 2001, 11 (05) : 339 - 352
  • [40] Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility
    Wu, Mei-Hsuan
    Chou, Yu-Ching
    Yu, Cheng-Pung
    Yang, Tsan
    You, San-Lin
    Chen, Chien-Jen
    Sun, Chien-An
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2008, 17 (04) : 317 - 322